Cellular Dynamics International Presents Data Demonstrating the Utility of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Hepatocytes as Human Cell Models at the Society of Toxicology 50th Annual Meeting & ToxExpo
CDI’s Manufacturing Process Generates Human Cells in the Quantity, Quality and Purity Required for High Throughput Drug Discovery and Toxicity Testing
MADISON, WIS., Mar. 3, 2011 – Cellular Dynamics International (CDI), the world’s largest producer of human induced pluripotent stem cell (iPSC)-derived tissue cells for drug discovery and safety testing, today announced two studies to be presented during the Society of Toxicology 50th Annual Meeting & ToxExpo on March 6 to 10 in Washington, D.C. The first study (abstract #215) demonstrates the use of CDI’s commercially available iPSC-derived cardiomyocytes (iCell® Cardiomyocytes) to assess the potential of compounds to induce cardiac arrhythmias. Results from this study show that iCell Cardiomyocytes accurately identify compounds that disrupt normal cardiac electrical activity. The second study (abstract #1173) includes phenotypic and functional characterization of CDI’s iCell Hepatoyctes, which will be commercially available in late 2011. CDI’s unique manufacturing capability provides iPSC-derived tissue cells with the high quality, quantity and purity needed for use during drug discovery and toxicity testing.
“Cellular Dynamics International is focused on providing human cell models for drug discovery and toxicity testing to the pharmaceutical and academic research communities,” said Chris Parker, Chief Commercial Officer of CDI. “We have developed the capability to reliably manufacture human cells derived from iPSCs in the quantity, quality and purity required by our customers. These studies provide further evidence of their functionality and utility for these applications.”
Emile Nuwaysir, Chief Operating Officer of CDI said, “The scientists at CDI have been focused on developing human cells for use in high throughput drug discovery and toxicity testing. It is extremely important that our iCell products are well-characterized and validated both internally and with our pharmaceutical and academic partners. The studies presented here demonstrate functional characterization and utility of CDI’s iCell products for drug discovery and toxicity assessment. CDI’s iPSC technology and unique manufacturing capability offer access to unlimited quantities of biologically relevant in vitro model systems, including human cardiomyoyctes, hepatocytes and other cell types in development, such endothelial cells and neurons.”
Abstract #215: Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Assessing Drug Induced Cardiac Arrhythmias
Drug-induced cardiac arrhythmias are a significant adverse event risk for drug candidates. The identification of new chemical entities (NCEs) that pose this risk early in pre-clinical development is vital to prevent allocation of resources to such molecules and preventing them from being tested in humans. Current cell models employed for this work are derived from animals, immortal cell lines or cadaveric tissue. None adequately reflect human cells. During this study, the electrophysiological profile of cardiomyocytes derived from human iPSCs was characterized and their ability to respond to known ion channel blockers was assessed. Multiple endogenous ion currents were recorded from cardiomyocytes, and the currents responded as would be predicted to known ion channel blockers. The study demonstrated that human iPSC-derived cardiomyocytes are a suitable and novel human-based model for assessing NCE arrhythmogenic potential.
The details of this study will be presented from 9:30 a.m. to 12:30 p.m. on March 7 in Exhibition Hall.
Abstract #1173: Development and Characterization of Human Hepatocytes from Induced Pluripotent Stem Cells (iPSCs): A Novel in vitro Model System for Assessing Drug-Induced Hepatotoxicity
Drug-induced liver injury is the most common reason for drug failure during development and withdrawal of approved drugs. The failure to identify NCEs that may generate hepatotoxicity early in the drug discovery process is due at least in part to inadequate cellular models. Current models employ hepatocytes from human cadaveric tissue, primary animal cells or immortal cell lines. None reflect normal human biology. Human hepatocytes derived from iPSCs are a promising cell model that may better reflect normal human hepatocytes. During this study, human iPSC-derived hepatocytes, manufactured at more than 95% purity, were shown to exhibit hepatocyte morphology, gene and protein expression. The cells also responded as predicted to exposure to dexamethasone and rifampicin. These cells, which reflect human hepatocyte morphology, biochemistry and function, are promising tools to identify hepatotoxic NCEs early in development. The details of this study will be presented from 9:00 a.m. to 12:30 p.m. on March 8 in Exhibition Hall.
About Cellular Dynamics International, Inc.
Cellular Dynamics International, Inc. (CDI) is a leading developer of stem cell technologies for in vitro drug development, in vivo cellular therapeutics, and stem cell banking. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells in industrial quality, quantity and purity from any individual’s stem cell line created from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI’s facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.